Molecular characterization of low grade and high grade bladder cancer

Alessandro Apollo, Valerio Ortenzi, Cristian Scatena, Katia Zavaglia, Paolo Aretini, Francesca Lessi, Sara Franceschi, Sara Tomei, Carlo Alberto Sepich, Paolo Viacava, Chiara Maria Mazzanti, Antonio Giuseppe Naccarato

Research output: Contribution to journalArticle

3 Citations (Scopus)


Background Bladder cancer (BC) is the 9th most common cancer diagnosis worldwide. Low grade (LG) represents 70% of all BCs, characterized by recurrence and rare ability (10–15%) to progress to high grade (HG) and invade. The remaining 30% is high grade (HG), fast invasive BC, which is resistant to therapy. Identifying biomarkers for predicting those tumors able to progress is a key goal for patient outcome improvement. This study focuses on the most promising prognostic markers. Materials and methods TP53 and FGFR3 mutational status, Survivin, CK19, CK20, E-cadherin and CD44 gene expression analysis were performed on 66 BCs. Results Survivin was found associated to tumor grade (p<0.05). Moreover, Survivin correlated with CD44 in TP53 wild type (p = 0.0242) and FGFR3 wild type (p = 0.0036) tumors. In particular the Survivin-CD44 correlation was associated to HG FGFR3 wild type BCs (p = 0.0045). Unsupervised hierarchical clustering based on gene expression data identified four distinct molecular groups reflecting the patient histology (p = 0.038). Conclusion We suggest Survivin, both as a biomarker associated to G3 BCs but negatively related to TP53 mutational status, and as a potential novel therapeutic target.

Original languageEnglish
Article numbere0210635
JournalPLoS One
Issue number1
Publication statusPublished - 1 Jan 2019


ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Apollo, A., Ortenzi, V., Scatena, C., Zavaglia, K., Aretini, P., Lessi, F., Franceschi, S., Tomei, S., Sepich, C. A., Viacava, P., Mazzanti, C. M., & Naccarato, A. G. (2019). Molecular characterization of low grade and high grade bladder cancer. PLoS One, 14(1), [e0210635].